Abcam, the Cambridge based online antibody supplier, reported in an update regarding the interim results to December 2011 that they are anticipated to show sales growth of 13.5% (2010: £39.4 million). Improved gross and operating margins have also been achieved through tight cost control and some exchange rate benefit.
The year end catalogue totalled 81,818 products (2010: 69,160). Trading remains on track to meet the board's full year expectations.
The ABC share price has increased by 4.4% over the past year.
Abcam Plc is graded B by LCF Research. To learn more, follow the link.
